Key result
Apatinib combined with doxorubicin and cyclophosphamide led to stabilization of multiple bilateral nodules and dramatic clinical improvement in a patient with pulmonary epithelioid hemangioendothelioma.
Why the study?
Pulmonary epithelioid hemangioendothelioma is rare without an established standard treatment, and the efficacy of apatinib combined with doxorubicin/cyclophosphamide chemotherapy had not been reported.
Does apatinib combined with doxorubicin and cyclophosphamide improve clinical symptoms and stabilize nodules in a patient with pulmonary epithelioid hemangioendothelioma?
Case Report (n=1)
Does apatinib combined with doxorubicin and cyclophosphamide improve clinical symptoms and stabilize nodules in a patient with pulmonary epithelioid hemangioendothelioma?
Apatinib combined with doxorubicin and cyclophosphamide may be an effective therapeutic option for stabilizing pulmonary epithelioid hemangioendothelioma.
Answers are grounded in this paper and cite their sources.
May support apatinib regimens in rare pulmonary epithelioid hemangioendothelioma; hypothesis-generating and requires prospective validation.
BACKGROUND: Pulmonary epithelioid hemangioendothelioma (P-EHE) is a rare disease. Thus far, consensus on a standard treatment for P-EHE has not been established given its low incidence worldwide. Apatinib combined with chemotherapy with doxorubicin/cyclophosphamide has been used as an effective combination treatment for human malignancies. However, the efficacy of this combination has not been reported in P-EHE cases. CASE SUMMARY: We present the case of a 64-year-old woman with chest tightness, cough, and chest pain. Computed tomography showed multiple unresectable pulmonary nodules. She had been misdiagnosed with lung carcinoma and underwent gefitinib treatment at a hospital. Subsequently, the patient underwent a cardiothoracic surgery for further disease investigation. CD31, CD34, and Vimentin expression were detected in the resected nodule specimens by immunohistochemical analyses, and pathological analyses confirmed the diagnosis of P-EHE. Following this, four cycles of apatinib combined with chemotherapy with doxorubicin/cyclophosphamide were initiated. The patient demonstrated stabilization of multiple bilateral nodules and showed a dramatic improvement in the clinical presentation after combination treatment. The patient could not tolerate the side effects of chemotherapy. Therefore, she then continued apatinib monotherapy, which is ongoing to date. The patient was stable at the last follow-up after 24 mo. CONCLUSION: Apatinib combined with chemotherapy with doxorubicin/cyclophosphamide may be an effective therapeutic option for P-EHE treatment.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2020) conducted a case report in Pulmonary epithelioid hemangioendothelioma (n=1). Apatinib combined with doxorubicin and cyclophosphamide was evaluated on Clinical response and tumor stabilization. Apatinib combined with doxorubicin and cyclophosphamide led to stabilization of multiple bilateral nodules and dramatic clinical improvement in a patient with pulmonary epithelioid hemangioendothelioma.
Synapse has enriched 10 related papers. Consider them for comparative context: